Eyenovia touts publication of intraocular pressure data for micro-dose tech

Eyenovia (NSDQ:EYEN) said this week that the results of its Phase II PG21 study were published in the Nov. issue of the journal Clinical Ophthalmology. The New York-based company’s Phase II study evaluated the effect of self-administered micro-dose latanoprost on intraocular pressure. Get the full story at our sister site, Drug Delivery Business News. The post Eyenovia touts publication of intraocular pressure data for micro-dose tech appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Eyenovia Inc. Source Type: news